Start here if you're new
what it is
It tries to deliver medicines inside cells so hard-to-reach diseases can be treated.
how it gets paid
Last year Entrada Therapeutics made $25M in revenue.
why growth slowed
Revenue fell 87.9% last year. Sales were up 1,395% from the last comparable quarter, but the business is still deep in loss mode.
what just happened
$24M revenue is real, but the company still lost $2.53 per share.
At a glance
C++ balance sheet — some cracks in the foundation
15.3% return on capital — nothing to write home about
$1.68 fy2024 eps est
$211M fy2024 rev est
n/a operating margin
xvary composite: 41/100 — below average
What they do
It tries to deliver medicines inside cells so hard-to-reach diseases can be treated.
EEV means endosomal escape vehicle, or a drug delivery system. So what: it is built to push medicines into cells that usually reject them. Entrada says 4 DMD programs are coming in 2026, while revenue is only $25M today. If you own it, you are betting your money on that gap closing.
How they make money
$25M
annual revenue · revenue declined -87.9% last year
total revenue
$25M
87.9%
The products that matter
Duchenne muscular dystrophy candidate
ENTRADA-001
2026 cohort 1 data catalyst
This is the readout the market cares about. With the whole company worth about $486M and no commercial product, a meaningful share of that valuation sits on this program proving the platform works.
lead catalyst
partnered myotonic dystrophy program
VX-670
Vertex-backed pipeline exposure
Vertex is the external validation here. That matters because current collaboration revenue was only $1.3M in the latest quarter, so the partnership is more important as proof than as present cash flow.
partner validation
intracellular delivery platform
platform science
$25M trailing revenue base
This is the actual bet. If the platform can repeatedly move therapies into the right cells, today’s $25M revenue base stops mattering and future deal economics matter a lot more.
platform bet
Key numbers
$25M
annual revenue
That is the size of the whole business today, per EDGAR.
n/a
op margin
Prior margin KPI failed sanity check — verify in filings. For every $1 of sales, operating profit lost $6.21.
$48M
long debt
Debt is 9% of capital, so leverage is real but not fatal.
5/100
price stability
VL's 5 out of 100 says the stock moves like a shopping cart with one bad wheel.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $48M (9% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for TRDA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
$24M revenue is real, but the company still lost $2.53 per share.
Sales were up 1,395% from the last comparable quarter, but the business is still deep in loss mode. Gross margin was not disclosed in the data.
$24.0M
revenue
-$2.53
eps
n/a
n/a
top line
The $24M revenue line matters because it proves the platform can sell, while losses still dominate.
source: EDGAR quarterly filing, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is lead Duchenne data failing to validate the delivery platform.
med
Lead clinical readout disappoints
This company has no approved product and just $25M of trailing revenue. If the Duchenne program fails to show convincing signal, investors stop paying for platform potential and start valuing cash burn.
Impact: most of the current ~$486M valuation is tied to future credibility, not present cash flow.
med
Funding pressure after weak revenue
Trailing EPS is -$3.79 and quarterly collaboration revenue was only $1.3M. Clinical-stage biotech math is unforgiving when revenue disappears before the next catalyst arrives.
Impact: additional financing could dilute shareholders or force less attractive partnership economics.
med
Vertex dependency cuts both ways
The Vertex relationship validates the science, but it also means part of the story sits outside Entrada’s direct control. Timelines, economics, and strategic priority can shift on the partner’s schedule.
Impact: even good science can create a slower or less lucrative outcome if partner priorities move.
A setback here does not pressure a mature revenue base. It pressures a company with $25M of trailing revenue, no approved product, and a valuation that assumes future proof.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
2026 Duchenne cohort 1 data
This is the event that can change the stock’s identity. Good data make the platform feel real. Bad data make $25M of trailing revenue feel very small.
metric
Collaboration revenue recovery
The latest quarter printed only $1.3M after a 94% drop. You want to see whether revenue noise is just milestone timing or a sign the partnership engine is stalling.
trend
Street expectations versus reality
The stock trades at $10.88 while the average analyst target sits at $18.50. That gap stays interesting only if updates keep supporting the 2026 catalyst path.
risk
Financing pressure
C++ balance sheet grade, -$3.79 trailing EPS, and no commercial product mean balance sheet headlines can take over quickly if data slip.
Analyst rankings
street consensus
5 analysts
Coverage exists, but it is still a small crowd. In human-speak, this is a niche biotech name, not a broadly followed compounder.
average target
$18.50
That sits roughly 70% above the current $10.88 price. Analysts are underwriting catalyst success, not near-term revenue quality.
price stability
5 / 100
This stock does not trade like a defensive healthcare name. It trades like a binary trial setup.
source: institutional data
Institutional activity
institutional ownership data for TRDA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$11
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive